They raised sales guidance $3 billion and left adjusted operating income and EPS exactly where they were, then refused to guide free cash flow at all.
Thesis: The second-half 'explosive growth' is cadence reshuffle, not incremental profit. They raised sales $3B off brand inflation and Summit and held AOI at $4.7-$4.9B and EPS at $4.45-$4.65, so the 30% H2 EPS print mostly unwinds a cost-heavy H1. Underneath that optics swing: negative free cash flow with no guide, healthcare AOI losses widening from $13M to $152M, interest expense up $70-$80M, and the AmerisourceBergen stake cut 26% to 17% to fund a $3.5B acquisition.
Verdict: SHORT — Conviction: MEDIUM
Catalyst: Q2 print. Management already guided it 'a little bit below the street.' The test is whether scripts track the 5% target and whether the $350M reimbursement swing lands as modeled, plus any free cash flow disclosure for the full year.
Key Risk: Q2 scripts print above the 5% target and Summit synergies exceed the $150M floor. That combination validates the H2 bridge as real upside rather than timing, and the short gets run over on a beat-and-raise.
The Tell: Kehoe, unprompted: 'there's a perception out there that it was overly dependent on tax rate, and I do want to give you our position... only three cents was from tax.' Minutes later on the same call: 'the beat of $0.04 was, you can say, all due to tax.' He argued both sides and then conceded the bear's number.
Friction Level: MODERATE_FRICTION — Both sides accept the $850M second-half bridge. Bull reads the timing reversals as earnings inflection. Bear reads them as H1 costs shifting, not full-year profit, which is why EPS guidance stayed at $4.45-$4.65 on a $3B sales raise.
Report not found
The report data is no longer available. Please return to the archive.